Polypeptide‑GalNAc‑T6 expression predicts better overall survival in patients with colon cancer
- Authors:
- Luis Ubillos
- Edgardo Berriel
- Daniel Mazal
- Sabina Victoria
- Enrique Barrios
- Eduardo Osinaga
- Nora Berois
-
Affiliations: Departamento de Inmunobiología, Facultad de Medicina, Universidad de la República, Montevideo 11800, Uruguay, Clínica Quirúrgica 1, Hospital Pasteur, Facultad de Medicina, Universidad de la República, Montevideo 11400, Uruguay, Cátedra de Anatomía Patológica, Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo 11600, Uruguay, Unidad de Biología Celular, Institut Pasteur de Montevideo, Montevideo 11400, Uruguay, Departamento de Métodos Cuantitativos, Facultad de Medicina, Universidad de la República, Montevideo 11800, Uruguay, Laboratorio de Glicobiología e Inmunología Tumoral, Institut Pasteur de Montevideo, Montevideo 11400, Uruguay - Published online on: May 10, 2018 https://doi.org/10.3892/ol.2018.8686
- Pages: 225-234
-
Copyright: © Ubillos et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
Byrd JC and Bresalier RS: Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev. 23:77–99. 2004. View Article : Google Scholar : PubMed/NCBI | |
Dube DH and Bertozzi CR: Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat Rev Drug Discov. 4:477–488. 2005. View Article : Google Scholar : PubMed/NCBI | |
Pinho SS and Reis CA: Glycosylation in cancer: Mechanisms and clinical implications. Nat Rev Cancer. 15:540–555. 2015. View Article : Google Scholar : PubMed/NCBI | |
Kufe DW: Mucins in cancer: Function, prognosis and therapy. Nat Rev Cancer. 9:874–885. 2009. View Article : Google Scholar : PubMed/NCBI | |
Freire-de-Lima L, Gelfenbeyn K, Ding Y, Mandel U, Clausen H, Handa K and Hakomori SI: Involvement of O-glycosylation defining oncofetal fibronectin in epithelial-mesenchymal transition process. Proc Natl Acad Sci USA. 108:17690–17695. 2001. View Article : Google Scholar | |
Brockhausen I: Mucin-type O-glycans in human colon and breast cancer: Glycodynamics and functions. EMBO Rep. 7:599–604. 2006. View Article : Google Scholar : PubMed/NCBI | |
Itzkowitz SH, Yuan M, Montgomery CK, Kjeldsen T, Takahashi HK, Bigbee WL and Kim YS: Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer. Cancer Res. 49:197–204. 1989.PubMed/NCBI | |
Fu C, Zhao H, Wang Y, Cai H, Xiao Y, Zeng Y and Chen H: Tumor-associated antigens: Tn antigen, sTn antigen, and T antigen. HLA. 88:275–286. 2016. View Article : Google Scholar : PubMed/NCBI | |
Meichenin M, Rocher J, Galanina O, Bovin N, Nifantev N, Sherman A, Cassagnau E, Heymann MF, Bara J, Fraser RH and Le Pendu J: Tk, a new colon tumor-associated antigen resulting from altered O-glycosylation. Cancer Res. 60:5499–5507. 2000.PubMed/NCBI | |
Medina M, Vélez D, Asenjo JA, Egea G, Real FX, Gil J and Subiza JL: Human colon adenocarcinomas express a MUC1-associated novel carbohydrate epitope on core mucin glycans defined by a monoclonal antibody (A10) raised against murine Ehrlich tumor cells. Cancer Res. 59:1061–1070. 1999.PubMed/NCBI | |
Tarp MA and Clausen H: Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochim Biophys Acta. 1780:546–563. 2008. View Article : Google Scholar : PubMed/NCBI | |
Kimura T, McKolanis JR, Dzubinski LA, Islam K, Potter DM, Salazar AM, Schoen RE and Finn OJ: MUC1 vaccine for individuals with advanced adenoma of the colon: A cancer immunoprevention feasibility study. Cancer Prev Res (Phila). 6:18–26. 2013. View Article : Google Scholar : PubMed/NCBI | |
Bennett EP, Mandel U, Clausen H, Gerken TA, Fritz TA and Tabak LA: Control of mucin-type O-glycosylation: A classification of the polypeptide GalNAc-transferase gene family. Glycobiology. 22:736–756. 2012. View Article : Google Scholar : PubMed/NCBI | |
Van den Steen P, Rudd PM, Dwek RA and Opdenakker G: Concepts and principles of O-linked glycosylation. Crit Rev Biochem Mol Biol. 33:151–208. 1998. View Article : Google Scholar : PubMed/NCBI | |
Johansson ME, Larsson JM and Hansson GC: The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. Proc Natl Acad Sci USA. 108 Suppl 1:S4659–S4665. 2011. View Article : Google Scholar | |
Brockhausen I, Schachter H and Stanley P: Chapter 9 O-GalNAc glycansEssentials of Glycobiology. 2nd edition. Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW and Etxler ME: Cold Spring Harbor, New York: Laboratory Press; 2009 | |
Xia L: Core 3-derived O-glycans are essential for intestinal mucus barrier function. Methods Enzymol. 479:123–141. 2010. View Article : Google Scholar : PubMed/NCBI | |
Holst S, Wuhrer M and Rombouts Y: Glycosylation characteristics of colorectal cancer. Adv Cancer Res. 126:203–256. 2015. View Article : Google Scholar : PubMed/NCBI | |
Bergstrom K, Liu X, Zhao Y, Gao N, Wu Q, Song K, Cui Y, Li Y, McDaniel JM, McGee S, et al: Defective intestinal mucin-type O-glycosylation causes spontaneous colitis-associated cancer in mice. Gastroenterology. 151:152–164.e11. 2016. View Article : Google Scholar : PubMed/NCBI | |
Fu J, Wei B, Wen T, Johansson ME, Liu X, Bradford E, Thomsson KA, McGee S, Mansour L, Tong M, et al: Loss of intestinal core 1-derived O-glycans causes spontaneous colitis in mice. J Clin Invest. 121:1657–1666. 2011. View Article : Google Scholar : PubMed/NCBI | |
Nishida A, Lau CW, Zhang M, Andoh A, Shi HN, Mizoguchi E and Mizoguchi A: The membrane-bound mucin Muc1 regulates T helper 17-cell responses and colitis in mice. Gastroenterology. 142:865–874.e2. 2012. View Article : Google Scholar : PubMed/NCBI | |
Velcich A, Yang W, Heyer J, Fragale A, Nicholas C, Viani S, Kucherlapati R, Lipkin M, Yang K and Augenlicht L: Colorectal cancer in mice genetically deficient in the mucin Muc2. Science. 295:1726–1729. 2002. View Article : Google Scholar : PubMed/NCBI | |
An G, Wei B, Xia B, McDaniel JM, Ju T, Cummings RD, Braun J and Xia L: Increased susceptibility to colitis and colorectal tumors in mice lacking core 3-derived O-glycans. J Exp Med. 204:1417–1429. 2007. View Article : Google Scholar : PubMed/NCBI | |
Guda K, Moinova H, He J, Jamison O, Ravi L, Natale L, Lutterbaugh J, Lawrence E, Lewis S, Willson JK, et al: Inactivating germ-line and somatic mutations in polypeptide N-acetylgalactosaminyltransferase 12 in human colon cancers. Proc Natl Acad Sci USA. 106:12921–12925. 2009. View Article : Google Scholar : PubMed/NCBI | |
Venkitachalam S and Guda K: Altered glycosyltransferases in colorectal cancer. Expert Rev Gastroenterol Hepatol. 11:5–7. 2017. View Article : Google Scholar : PubMed/NCBI | |
Mandel U, Hassan H, Therkildsen MH, Rygaard J, Jakobsen MH, Juhl BR, Dabelsteen E and Clausen H: Expression of polypeptide GalNAc-transferases in stratified epithelia and squamous cell carcinomas: Immunohistological evaluation using monoclonal antibodies to three members of the GalNAc-transferase family. Glycobiology. 9:43–52. 1999. View Article : Google Scholar : PubMed/NCBI | |
Berois N, Mazal D, Ubillos L, Trajtenberg F, Nicolas A, Sastre-Garau X, Magdelenat H and Osinaga E: UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-6 as a new immunohistochemical breast cancer marker. J Histochem Cytochem. 54:317–328. 2006. View Article : Google Scholar : PubMed/NCBI | |
Wu C, Guo X, Wang W, Wang Y, Shan Y, Zhang B, Song W, Ma S, Ge J, Deng H and Zhu M: N-Acetylgalactosaminyltransferase-14 as a potential biomarker for breast cancer by immunohistochemistry. BMC Cancer. 10:1232010. View Article : Google Scholar : PubMed/NCBI | |
Hussain MR, Hoessli DC and Fang M: N-acetylgalacto-saminyltransferases in cancer. Oncotarget. 7:54067–54081. 2016. View Article : Google Scholar : PubMed/NCBI | |
Taniuchi K, Cerny RL, Tanouchi A, Kohno K, Kotani N, Honke K, Saibara T and Hollingsworth MA: Overexpression of GalNAc-transferase GalNAc-T3 promotes pancreatic cancer cell growth. Oncogene. 30:4843–5484. 2011. View Article : Google Scholar : PubMed/NCBI | |
Gu C, Oyama T, Osaki T, Li J, Takenoyama M, Izumi H, Sugio K, Kohno K and Yasumoto K: Low expression of polypeptide GalNAc N-acetylgalactosaminyl transferase-3 in lung adenocarcinoma: Impact on poor prognosis and early recurrence. Br J Cancer. 90:436–442. 2004. View Article : Google Scholar : PubMed/NCBI | |
Zhao S, Guo T, Li J, Uramoto H, Guan H, Deng W and Gu C: Expression and prognostic value of GalNAc-T3 in patients with completely resected small (≤2 cm) peripheral lung adenocarcinoma after IASLC/ATS/ERS classification. Onco Targets Ther. 8:3143–3152. 2015. View Article : Google Scholar : PubMed/NCBI | |
Miyahara N, Shoda J, Kawamoto T, Furukawa M, Ueda T, Todoroki T, Tanaka N, Matsuo K, Yamada Y, Kohno K and Irimura T: Expression of UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase isozyme 3 in the subserosal layer correlates with postsurgical survival of pathological tumor stage 2 carcinoma of the gallbladder. Clin Cancer Res. 10:2090–2099. 2004. View Article : Google Scholar : PubMed/NCBI | |
He H, Shen Z, Zhang H, Wang X, Tang Z, Xu J and Sun Y: Clinical significance of polypeptide N-acetylgalactosaminyl transferase-5 (GalNAc-T5) expression in patients with gastric cancer. Br J Cancer. 110:2021–2029. 2014. View Article : Google Scholar : PubMed/NCBI | |
Lee ES, Son DS, Kim SH, Lee J, Jo J, Han J, Kim H, Lee HJ, Choi HY, Jung Y, et al: Prediction of recurrence-free survival in postoperative non-small cell lung cancer patients by using an integrated model of clinical information and gene expression. Clin Cancer Res. 14:7397–7404. 2008. View Article : Google Scholar : PubMed/NCBI | |
Kwon OS, Oh E, Park JR, Lee JS, Bae GY, Koo JH, Kim H, Choi YL, Choi YS, Kim J and Cha HJ: GalNAc-T14 promotes metastasis through Wnt dependent HOXB9 expression in lung adenocarcinoma. Oncotarget. 6:41916–41928. 2015. View Article : Google Scholar : PubMed/NCBI | |
Freire T, Berois N, Sóñora C, Varangot M, Barrios E and Osinaga E: UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 (ppGalNAc-T6) mRNA as a potential new marker for detection of bone marrow-disseminated breast cancer cells. Int J Cancer. 119:1383–1388. 2006. View Article : Google Scholar : PubMed/NCBI | |
Berois N, Blanc E, Ripoche H, Mergui X, Trajtenberg F, Cantais S, Barrois M, Dessen P, Kågedal B, Bénard J, et al: ppGalNAc-T13: A new molecular marker of bone marrow involvement in neuroblastoma. Clin Chem. 52:1701–1172. 2006. View Article : Google Scholar : PubMed/NCBI | |
Berois N, Gattolliat CH, Barrios E, Capandeguy L, Douc-Rasy S, Valteau-Couanet D, Bénard J and Osinaga E: GALNT9 gene expression is a prognostic marker in neuroblastoma patients. Clin Chem. 59:225–233. 2013. View Article : Google Scholar : PubMed/NCBI | |
Kohsaki T, Nishimori I, Nakayama H, Miyazaki E, Enzan H, Nomoto M, Hollingsworth MA and Onishi S: Expression of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase isozymes T1 and T2 in human colorectal cancer. J Gastroenterol. 35:840–848. 2000. View Article : Google Scholar : PubMed/NCBI | |
Bennett EP, Hassan H and Clausen H: cDNA cloning and expression of a novel human UDP-N-acetyl-alpha-D-galactosamine. Polypeptide N-acetylgalactosaminyltransferase, GalNAc-t3. J Biol Chem. 271:17006–17012. 1996. View Article : Google Scholar : PubMed/NCBI | |
Guo JM, Chen HL, Wang GM, Zhang YK and Narimatsu H: Expression of UDP-GalNAc:polypeptide N-acetyl-galactosaminyltransferase-12 in gastric and colonic cancer cell lines and in human colorectal cancer. Oncology. 67:271–276. 2004. View Article : Google Scholar : PubMed/NCBI | |
Kato K, Takeuchi H, Kanoh A, Miyahara N, Nemoto-Sasaki Y, Morimoto-Tomita M, Matsubara A, Ohashi Y, Waki M, Usami K, et al: Loss of UDP-GalNAc:polypeptide N-acetyl-galactosaminyltransferase 3 and reduced O-glycosylation in colon carcinoma cells selected for hepatic metastasis. Glycoconj J. 27:267–276. 2010. View Article : Google Scholar : PubMed/NCBI | |
Shibao K, Izumi H, Nakayama Y, Ohta R, Nagata N, Nomoto M, Matsuo K, Yamada Y, Kitazato K, Itoh H and Kohno K: Expression of UDP-N-acetyl-alpha-D-galactosamine-polypeptide galNAc N-acetylgalactosaminyl transferase-3 in relation to differentiation and prognosis in patients with colorectal carcinoma. Cancer. 94:1939–1946. 2002. View Article : Google Scholar : PubMed/NCBI | |
Kato K, Takeuchi H, Kanoh A, Mandel U, Hassan H, Clausen H and Irimura T: N-acetylgalactosamine incorporation into a peptide containing consecutive threonine residues by UDP-N-acetyl-D-galactosaminide:polypeptide N-acetylgalactosaminyltransferases. Glycobiology. 11:821–829. 2001. View Article : Google Scholar : PubMed/NCBI | |
Kanoh A, Takeuchi H, Kato K, Waki M, Usami K and Irimura T: Interleukin-4 induces specific pp-GalNAc-T expression and alterations in mucin O-glycosylation in colonic epithelial cells. Biochim Biophys Acta. 1780:577–584. 2008. View Article : Google Scholar : PubMed/NCBI | |
Bennett EP, Hassan H, Mandel U, Hollingsworth MA, Akisawa N, Ikematsu Y, Merkx G, van Kessel AG, Olofsson S and Clausen H: Cloning and characterization of a close homologue of human UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase-T3, designated GalNAc-T6. Evidence for genetic but not functional redundancy. J Biol Chem. 274:25362–15370. 1999. View Article : Google Scholar : PubMed/NCBI | |
Brooks SA, Carter TM, Bennett EP, Clausen H and Mandel U: Immunolocalisation of members of the polypeptide N-acetyl-galactosaminyl transferase (ppGalNAc-T) family is consistent with biologically relevant altered cell surface glycosylation in breast cancer. Acta Histochem. 109:273–284. 2007. View Article : Google Scholar : PubMed/NCBI | |
Patani N, Jiang W and Mokbel K: Prognostic utility of glycosyltransferase expression in breast cancer. Cancer Genomics Proteomics. 5:333–340. 2008.PubMed/NCBI | |
Park JH, Nishidate T, Kijima K, Ohashi T, Takegawa K, Fujikane T, Hirata K, Nakamura Y and Katagiri T: Critical roles of mucin 1 glycosylation by transactivated polypeptide N-acetylgalactosaminyltransferase 6 in mammary carcinogenesis. Cancer Res. 70:2759–2769. 2010. View Article : Google Scholar : PubMed/NCBI | |
Park JH, Katagiri T, Chung S, Kijima K and Nakamura Y: Polypeptide N-acetylgalactosaminyltransferase 6 disrupts mammary acinar morphogenesis through O-glycosylation of fibronectin. Neoplasia. 13:320–326. 2011. View Article : Google Scholar : PubMed/NCBI | |
Li Z, Yamada S, Wu Y, Wang KY, Liu YP, Uramoto H, Kohno K and Sasaguri Y: Polypeptide N-acetylgalactosaminyltransferase-6 expression independently predicts poor overall survival in patients with lung adenocarcinoma after curative resection. Oncotarget. 7:54463–54473. 2016.PubMed/NCBI | |
Li Z, Yamada S, Inenaga S, Imamura T, Wu Y, Wang KY, Shimajiri S, Nakano R, Izumi H, Kohno K and Sasaguri Y: Polypeptide N-acetylgalactosaminyltransferase 6 expression in pancreatic cancer is an independent prognostic factor indicating better overall survival. Br J Cancer. 104:1882–1889. 2011. View Article : Google Scholar : PubMed/NCBI | |
Kitada S, Yamada S, Kuma A, Ouchi S, Tasaki T, Nabeshima A, Noguchi H, Wang KY, Shimajiri S, Nakano R, et al: Polypeptide N-acetylgalactosaminyl transferase 3 independently predicts high-grade tumours and poor prognosis in patients with renal cell carcinomas. Br J Cancer. 109:472–481. 2013. View Article : Google Scholar : PubMed/NCBI | |
Wang ZQ, Bachvarova M, Morin C, Plante M, Gregoire J, Renaud MC, Sebastianelli A and Bachvarov D: Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: Possible implications in abnormal mucin O-glycosylation. Oncotarget. 5:544–560. 2014.PubMed/NCBI | |
Onitsuka K, Shibao K, Nakayama Y, Minagawa N, Hirata K, Izumi H, Matsuo K, Nagata N, Kitazato K, Kohno K and Itoh H: Prognostic significance of UDP-N-acetyl-alpha-D-galactosamine: polypeptide N-acetylgalactosaminyltransferase-3 (GalNAc-T3) expression in patients with gastric carcinoma. Cancer Sci. 94:32–36. 2003. View Article : Google Scholar : PubMed/NCBI | |
Gill DJ, Chia J, Senewiratne J and Bard F: Regulation of O-glycosylation through Golgi-to-ER relocation of initiation enzymes. J Cell Biol. 189:843–858. 2010. View Article : Google Scholar : PubMed/NCBI | |
Punt CJ, Koopman M and Vermeulen L: From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol. 14:235–246. 2017. View Article : Google Scholar : PubMed/NCBI | |
Mahasneh A, Al-Shaheri F and Jamal E: Molecular biomarkers for an early diagnosis, effective treatment and prognosis of colorectal cancer: Current updates. Exp Mol Pathol. 102:475–483. 2017. View Article : Google Scholar : PubMed/NCBI | |
Sinicrope FA, Okamoto K, Kasi PM and Kawakami H: Molecular biomarkers in the personalized treatment of colorectal cancer. Clin Gastroenterol Hepatol. 14:651–658. 2016. View Article : Google Scholar : PubMed/NCBI | |
Dienstmann R, Salazar R and Tabernero J: Personalizing colon cancer adjuvant therapy: Selecting optimal treatments for individual patients. J Clin Oncol. 33:1787–1796. 2015. View Article : Google Scholar : PubMed/NCBI | |
Lavrsen K, Dabelsteen S, Vakhrushev SY, Levann AMR, Haue AD, Dylander A, Mandel U, Hansen L, Frödin M, Bennett EP and Wandall HH: De novo expression of human polypeptide N-acetylgalactosaminyltransferase 6 (GalNAc-T6) in colon adenocarcinoma inhibits the differentiation of colonic epithelium. J Biol Chem. 293:1298–1314. 2018. View Article : Google Scholar : PubMed/NCBI | |
Andre T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, Scriva A, Hickish T, Tabernero J, Van Laethem JL, et al: Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: Updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol. 33:4176–4187. 2015. View Article : Google Scholar : PubMed/NCBI | |
Verhoeff SR, van Erning FN, Lemmens VE, de Wilt JH and Pruijt JF: Adjuvant chemotherapy is not associated with improved survival for all high-risk factors in stage II colon cancer. Int J Cancer. 139:187–193. 2016. View Article : Google Scholar : PubMed/NCBI | |
Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, et al: The consensus molecular subtypes of colorectal cancer. Nat Med. 21:1350–1356. 2015. View Article : Google Scholar : PubMed/NCBI |